Clinical Trial Update: Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2) [Phase 3]

View source ↗

Summary

CRUISE 2 is a Phase 3 trial evaluating continuous soluble ferric pyrophosphate delivered via dialysate for iron delivery in hemodialysis patients; the study com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate (ferric pyrophosphate)

Snippet

Sponsor: Rockwell Medical Technologies, Inc. | Conditions: Renal Failure Chronic Requiring Hemodialysis | Phase 3 | Status: COMPLETED | Results posted: 2015-04-24